Perrigo Company plc (PRGO)
Pre-market:
| Previous close | 32.66 |
| Open | 32.52 |
| Bid | 0.00 x 1000 |
| Ask | 33.96 x 3200 |
| Day's range | 32.52 - 33.17 |
| 52-week range | 25.77 - 40.28 |
| Volume | |
| Avg. volume | 1,952,359 |
| Market cap | 4.458B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.10 (3.36%) |
| Ex-dividend date | 31 May 2024 |
| 1y target est | N/A |
- PR Newswire
Perrigo Announces Quarterly Dividend
Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024.
- PR Newswire
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that pharmaceutical company Esteve Healthcare, S.L. ("ESTEVE") has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million and up to €85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones.
- PR Newswire
Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024 financial results on Tuesday, May 7th, 2024, and host a conference call beginning at 8:30 A.M. (EDT).
